DENVER, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Phoenix Life Sciences International Limited (“Phoenix Life”) (OTCMarkets: MJMD), an adaptive global healthcare solutions company, today announced that its Chief Executive Officer Martin Tindall will be speaking on an expert panel about pharmaceutical cannabis research at the Cannabis World Congress and Business Expo, taking place in Los Angeles on Thursday, Sept. 27, at 2 p.m. PT.
“As cannabis research and innovation continues to flourish in the U.S. and throughout the world, I am proud to be at the forefront of this conversation and help people understand the many underutilized tools and resources that are available with plant-based medicines,” said Martin Tindall, incoming Chief Executive Officer of Phoenix Life Sciences International. “We hope that Phoenix will soon become a widely recognized leader in this space and help improve global healthcare.”
The Cannabis World Congress and Business Expo is one of the largest business-to-business trade show events for the cannabis industry, with entrepreneurs, investors, media and other stakeholders from all over the country in attendance. The panel, titled “Pharmaceutical Research” will feature several industry experts and will explore the many facets of current cannabis research and the gaps which still need to be filled. The panelists, including Tindall, will also discuss the challenges of doing research in the U.S. versus in other countries around the world.
Currently, Phoenix Life Sciences International is working to become the leader in outdoor-grown pharmaceutical cannabis-derived drugs targeted at diabetes. The company is working with the Republic of Vanuatu’s governmental agencies to help the nation treat its more than 35,000 diabetes patients with a low-cost alternative natural treatment. Once the company’s diabetes drug has undergone several clinical studies, the company plans to then align with federal and state single-payer healthcare systems in established and emerging economies in order to bring it to market.
The Cannabis World Congress and Business Expo Exhibit Hall will be open from 11 a.m. to 5 p.m. on Thursday, Sept. 27, and Friday, Sept. 28, and from 10 a.m. to 4 p.m. on Saturday, Sept. 29.
For more information about Phoenix Life, please visit https://www.plsi.co/.
About Phoenix Life Sciences International Limited
Phoenix Life Sciences International Limited is an adaptive global healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.
FORWARD-LOOKING STATEMENTS
Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International are not available on U.S.
LEGAL DISCLOSURE
Phoenix Life Sciences International does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). This company does grow, sell, and distribute cannabis-based products in the United States and is solely involved with the legal distribution of medical cannabis-based products within certain international markets outside of the United States.
Investor Contact:
Phone: 1.888.717.5655 or international +1.720.699.7222
E-mail: investor.relations@phoenixlife.co
Media Contact:
Kathryn Reinhardt
CMW Media
Kathryn@cmwmedia.com
619-972-3089